A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL).

Trial Profile

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL).

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications Hairy cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 05 Jun 2018 Results of population PK model by using pooled data from two studies including this study presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 27 Feb 2018 Results of long term follow up published in the Blood
    • 12 Dec 2017 Results of retrospective analysis associating Minimal Residual Disease with Extended Response to Moxetumomab Pasudotox (n=37) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top